Nyxoah S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NYXH research report →
Range $2.31 – $4
Price Chart
About the company
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- CEO
- Liam J. Kelly
- IPO
- 2021
- Employees
- 154
- HQ
- Mont-Saint-Guibert, WA, BE
Get TickerSpark's AI analysis on NYXH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $81.98M
- P/E
- -0.43
- Fwd P/E
- 8.16
- PEG
- -0.02
- P/S
- 2.50
- P/B
- 1.09
- EV/EBITDA
- -1.66
- Div Yield
- 0.00%
- Gross Margin
- 54.32%
- Op Margin
- -282.89%
- Net Margin
- -310.64%
- ROE
- -157.03%
- ROIC
- -68.12%
Latest fiscal year · YoY change
- Revenue
- $10.02M+121.6%
- Gross Profit
- $6.33M+113.1%
- Op Income
- $-82,942,000
- Net Income
- $-90,085,000-52.1%
- EPS
- $-2.36-30.4%
- OCF Growth
- -37.1%
- FCF Growth
- -23.5%
- 52W High
- $5.39
- 52W Low
- $0.80
- 50D MA
- $1.13
- 200D MA
- $2.21
- Beta
- 1.02
- RSI (14)
- 30
- Avg Volume
- 318.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nyxoah reported strong U.S. launch momentum and margin improvement, but trimmed full-year revenue guidance as management reset expectations for a more typical commercial ramp.· November 5, 2026
- Q3 2026 revenue was EUR 9.2 million, up 19% sequentially and 365% year over year; U.S. revenue was EUR 6.7 million.
- Gross margin improved to 63.1% from 60.5% a year ago, helped by spreading manufacturing costs over higher device volume.
- Full-year 2026 revenue guidance was lowered to EUR 33 million-EUR 35 million, which management tied to a more historical new-technology ramp.
- Commercial buildout continued: 80 new surgeons trained in Q3, 53 new accounts activated, and 447 patients were in prior authorization as of quarter-end.
- Clinical and regulatory progress was a highlight: ACCCESS met primary efficacy and safety endpoints, and a PMA supplement was filed to expand Genio to CCC patients.
Third-quarter 2026 net revenue was EUR 9.2 million, up 365% from Q3 2025 and 19% sequentially. U.S. net revenue was EUR 6.7 million, up 29% sequentially, while international net revenue was EUR 2.5 million, up 42% year over year. Gross margin was 63.1% versus 60.5% in the prior-year quarter. Total operating loss was EUR 21.9 million versus EUR 24.4 million a year ago. Cash equivalents and financial assets were EUR 77.1 million at September 30, 2026, down from EUR 97.8 million at June 30, 2026. For full-year 2026, management guided to global net revenue of EUR 33 million-EUR 35 million and gross margin of 60%-62%.
Liam Kelly framed the call around the U.S. launch opportunity, saying he sees Genio at an inflection point in the U.S. and highlighted the product’s bilateral differentiation. He emphasized that CCC patients represent about one in four patients evaluated for therapy and said the PMA supplement could expand the addressable market and simplify workflow. His tone was constructive and confident, with repeated focus on execution, account penetration, and building a commercially focused organization.
Loïc Moreau said Q3 revenue of EUR 9.2 million reflected strong top-line growth, with gross margin at 63.1% versus 60.5% last year due to better absorption of manufacturing costs. He noted operating loss improved to EUR 21.9 million from EUR 24.4 million, and cash and financial assets declined to EUR 77.1 million from EUR 97.8 million at June 30, 2026. He reiterated full-year guidance for revenue of EUR 33 million-EUR 35 million and gross margin of 60%-62%, while stressing discipline on spending and a goal to reduce cash burn quarter over quarter.
Analysts focused on Liam Kelly’s new role and what drew him to Nyxoah, and he said the appeal was the chance to drive U.S. market penetration at what he sees as an inflection point. On 2027 expectations, management declined to give formal guidance but said investors should feel confident in achieving what they put forward for 2027, with further detail to come with Q4 results. Kelly also reiterated that the company is adding centers, training more doctors, and growing its sales force to 55 reps, while continuing to push for CCC label expansion.
Management believes Genio is meaningfully differentiated because it is the only bilateral HGNS therapy on the market, and early U.S. launch metrics show growing adoption. The company cited strong surgeon training, expanding active accounts, improving gross margin, and positive clinical data from ACCCESS that could expand the label to CCC patients.
The company cut full-year revenue guidance to EUR 33 million-EUR 35 million, signaling a slower-than-previously expected U.S. ramp as physicians and centers build experience. Cash declined quarter over quarter, operating losses remain sizable, and management emphasized that it is still early in the launch and that 2027 guidance will not come until Q4 results.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 51.6%
- Shares Outstanding
- 101.84M
- Float Shares
- 52.55M
of shares held by institutions
45 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 14.63M | ▲ 98.00K |
| Bnp Paribas Asset Management Holding S.A. | 1.28M | ▲ 320.02K |
| Rossmore Private Capital | 714.14K | ▲ 581.39K |
| Syquant Capital Sas | 596.39K | ▲ 596.39K |
| Andera Partners | 522.06K | 0 |
| Vestal Point Capital, LP | 479.00K | ▼ 364.46K |
| Axxion S.A. | 252.93K | ▼ 651.97K |
| Federation Des Caisses Desjardins Du Quebec | 204.80K | ▲ 181.50K |
| Ifp Advisors, Inc | 119.63K | ▲ 1.21K |
| Integrated Wealth Concepts LLC | 103.78K | ▲ 3.78K |
| Ubs Group AG | 79.24K | ▲ 43.59K |
| Geode Capital Management, LLC | 69.09K | ▲ 24.29K |
Our NYXH coverage
Recent articles, reports, and earnings notes.
No research on NYXH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NYXH report →Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
globenewswire.com · Nov 18
Nyxoah SA (NYXH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 26
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher
zacks.com · Oct 20
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
globenewswire.com · Oct 19
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)
defenseworld.net · Oct 13
Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.
seekingalpha.com · Oct 5
Nyxoah Appoints Liam Kelly as Chief Executive Officer
globenewswire.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.